The natural history of progressive fibrosing interstitial lung diseases
Kevin K. Brown(Health Protection Surveillance Centre), Athol U. Wells(St Thomas' Hospital), Antje Prasse(University Medical Center Freiburg), Rainer-Georg Goeldner(Boehringer Ingelheim (Germany)), Rozsa Schlenker‐Herceg(Boehringer Ingelheim (United States)), Victor J. Thannickal(Tulane University), Fernando J. Martínez(University of Massachusetts Chan Medical School), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Vincent Cottin(Université Claude Bernard Lyon 1), Emmanuelle Clerisme-Beaty(Royal Brompton & Harefield NHS Foundation Trust), Simon Walsh(Royal Brompton & Harefield NHS Foundation Trust)
Cited by 288
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k